SSY Group (HKG:2005) said its 5-milliliter Composite Potassium Hydrogen Phosphate Injection and 5-milligram Vortioxetine Hydrobromide Tablets have obtained the National Medical Products Administration of China's approval for drug production and registration, a Monday Hong Kong bourse filing said.
The said injection is a compound used for the correction of hypophosphatemia in adult and child patients and parenteral nutrition in adult and child patients when enteral nutrition is impossible or insufficient.
The tablet is used for the treatment of depression in adults and has already obtained bulk drug approval from the authorities.
With the said approvals, the injection and the tablet, being under type 3 and type 4 chemical drugs respectively, are regarded as having passed the consistency evaluation.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。